LAG3 and COVID-19: Among the ligands of LAG-3, we observed significant decreases of MHC-II molecules on myeloid cells and B cells in progressive COVID-19 patients, which is also highlighted in our differential connectome analysis in progressive versus stable COVID-19 patients (Fig. 3c).